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Wound healing and local
neuroendocrine regulation in the
injured liver
Mohammad R. Ebrahimkhani, Ahmed M. Elsharkawy and Derek
A. Mann*
The hepatic wound-healing response is a complex process involving many
different cell types and factors. It leads to the formation of excessive matrix
and a fibrotic scar, which ultimately disrupts proper functioning of the liver and
establishes cirrhosis. Activated hepatic myofibroblasts, which are derived
from cells such as hepatic stellate cells (HSCs), play a key role in this process.
Upon chronic liver injury, there is an upregulation in the local neuroendocrine
system and it has recently been demonstrated that activated HSCs express
specific receptors and respond to different components of this system.
Neuroendocrine factors and their receptors participate in a complex network
that modulates liver inflammation and wound healing, and controls the
development and progression of liver fibrosis. The first part of this review
provides an overview of the molecular mechanisms governing hepatic wound
healing. In the second section, we explore important components of the
hepatic neuroendocrine system and their recently highlighted roles in HSC
biology and hepatic fibrogenesis. We discuss the therapeutic interventions
that are being developed for use in antifibrotic therapy.
Theliver,whichisthelargestsolidorganinthebody,
plays a central role in the regulation of metabolic
homeostasis and participates in many important
immunological functions. Hepatocytes comprise
about 70% of hepatic cells (Ref. 1). The remaining
30% is made up of nonparenchymal cells,
including hepatic stellate cells (HSCs), Kupffer
cells, endothelial cells, cholangiocytes and several
subsets of resident lymphocytes (Ref. 1) (Fig. 1).
Hepatocytes are organised into epithelial
plates and are primarily responsible for
metabolic functions in the liver. Between the
plates are the sinusoids, which are distensible
vascular channels lined with sinusoidal
endothelial cells (Fig. 1). Small fenestrations in
the sinusoidal linings allow direct cell-to-cell
contact and free diffusion of many substances.
Kupffer cells are resident liver macrophages
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that reside within the hepatic sinusoids and act
as a first line of defence against antigens
passing through the gastrointestinal barrier.
Between the endothelium and hepatocytes lies
the space of Disse where lymph is collected for
delivery to lymphatic capillaries. HSCs are
present within this space, store 80% of body
vitamin A and participate in hepatic wound
healing (Ref. 2), regulation of sinusoidal blood
flow (Ref. 2), angiogenesis (Ref. 3) and
hepatocyte growth (Ref. 4). The space of Disse
also contains basement-membrane-like matrix,
which is essential for the differentiated and
normal functions of all the hepatic cellular
compartments (Ref. 2).
Wound healing is the normal response of tissue
to an injury, and liver fibrosis occurs as a result of
repeated cycles of injury and repair. The cascade
of events that establish hepatic fibrosis is complex,
and is influenced byhowdifferent cell types in the
liver interact in response to injury.Hepatic fibrosis
and its end-stage – cirrhosis – are amajor cause of
mortality and morbidity worldwide. The most
common causes of cirrhosis are alcohol abuse,
hepatitis B, hepatitis C and, increasingly,
obesity, which leads to the metabolic syndrome
that can be complicated by non-alcoholic fatty
liver disease (NAFLD). Other less-common
causes include primary biliary cirrhosis,
haemochromatosis, autoimmune hepatitis and
primary sclerosing cholangitis.
Research over the past decade has greatly
improved our knowledge of the cellular and
molecular biology of fibrosis in the liver.
Several high-profile papers have shed new light
on the important roles that hepatic
neuroendocrine pathways play in the processes
of wound healing and regeneration in the liver.
These functions are also being increasingly
recognised in different organs (Refs 5, 6, 7). The
hepatic neuroendocrine system is upregulated
in the liver following injury and can regulate
the pattern of wound healing and hepatic
regeneration in different ways. In this review,
we will highlight some of the molecular
mechanisms underlying hepatic wound healing
and address recent advances in understanding
the role of the neuroendocrine system in liver
fibrosis. The fact that many modulators of
neuroendocrine factors are already in
widespread clinical use makes this field
particularly exciting. There is now, more than
ever, a need to generate effective antifibrotic
therapies in a world where mortality from liver
disease will see exponential growth as a result
of the current obesity epidemic, as well as
increasing burdens from alcohol abuse and
viral hepatitis.
Hepatic sinusoid and hepatocytes in the liver
Expert Reviews in Molecular Medicine © 2008 Cambridge University Press
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T cells
Space of Disse
Figure1.Thehepaticsinusoidandhepatocytes in the liver.Sinusoids (distensible vascularchannels) are lined
with sinusoidal endothelial cells. Kupffer cells (resident liver macrophages) reside within the hepatic sinusoids.
The space between the endothelium and hepatocytes is called the space of Disse. Hepatic stellate cells are
present in this space.
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Hepatic wound healing
The normal resolution of tissue injury involves a
series of precise orchestrated phases: (1)
inflammation; (2) production of cytokines and
growth factors; (3) myofibroblast activation; (4)
extracellular matrix (ECM) production; (5)
angiogenesis; (6) maturation; and (7)
remodelling, which eventually leads to scar
elimination and a return of injured tissue to the
normal state (Refs 8, 9) (Fig. 2). Inappropriate
tissue repair and pathological scarring occurs if
any element of this intricate process becomes
interrupted or overactivated. An imbalance
between ECM formation and degradation can
lead to the accumulation of ECM: an outcome
known as fibrosis (Ref. 9) (Fig. 2). Fibrosis is the
final general consequence of uncontrolled
repair processes in many organs in response to
a wide variety of chronic insults and ultimately
can disable proper functioning of the organ. It
is known to occur in the liver, pancreas, lungs,
heart, kidneys, eyes and skin. Over the past
decade, there has been extensive investigation
of the molecular events underlying tissue
fibrogenesis. In the following sections, we
explore the mechanism of hepatic wound
healing and describe the cellular compartments
in which it occurs.
The inflammation–fibrosis pathway
Chronic persistent inflammation typically
precedes fibrosis (Refs 10, 11, 12). Following
injury to the liver, hepatocytes release factors
that start an inflammatory process by
recruitment of leukocytes to the site of injury.
Local production of matrix metalloproteinases
(MMPs) at the site of injury results in the
disruption of the basement membrane and
favours inflammatory cell infiltration (Ref. 13).
Neutrophils are the most abundant
inflammatory cell in the early stages of wound
healing. Their granulation is followed by
macrophage infiltration and subsequently by
lymphocyte recruitment (Refs 8, 12). The
primary roles of leukocytes are to eliminate any
invading organisms and to remove dead cells
(Ref. 12). Inflammation also produces
profibrogenic cytokines and chemokines, which
activate myofibroblasts and induce wound-
healing responses, which, if unchecked, drive
fibrogenesis (Fig. 2). However, it has also been
proposed that fibrosis is not always driven by
inflammation, suggesting that the mechanisms
that regulate fibrogenesis partly differ from
those regulating inflammation (Ref. 8). This
might explain the lack of efficacy of some anti-
inflammatory agents in the treatment of fibrotic
disease and the need to identify targeted
antifibrotic therapies.
Myofibroblasts: the key players in hepatic
fibrosis
In many organs, including the liver,
myofibroblasts are the key cellular effectors
during wound contraction and repair, and
inappropriate myofibroblast activation is the
central pathogenic mechanism of fibrotic
disorders (Ref. 14). Upon tissue injury,
myofibroblasts become activated and migrate
toward the site of damage where they
proliferate. Myofibroblasts produce ECM
proteins, such as type I and type III collagen,
and control ECM remodelling through the
expression of several MMPs and tissue
inhibitors of metalloproteinases (TIMPs). The
balance between ECM degradation and
production is a critical factor that determines
the normal wound-healing response and
returns the tissue to its preinjury state (Ref. 15).
This process is influenced by the number of
activated myofibroblasts at the site of injury,
which is controlled by the rate of production
and proliferation as well as apoptosis of these
cells (Refs 9, 16). Chronic injury induces a
marked alteration in the normal healing process
and prevents return of tissue to the preinjury
state. In fact, constant inflammation and/or
infection leads to permanent myofibroblast
activation, either directly, by acting on HSCs or
indirectly, through paracarine-dependent factors
(Fig 2). This activated phenotype of
myofibroblasts promotes the inappropriate
regulation of tissue repair and leads to
extensive scar formation, and finally results in
fibrosis (Ref. 17) (Fig. 2).
Developmentally, fibroblasts are mesenchymal
in origin (Ref. 18). However, it is now widely
believed that myofibroblasts are derived from a
number of different sources in injured adult
tissues (Ref. 19). In the context of the liver, there
are four different cellular sources (Fig. 3). HSCs
are well-characterised cells that have been
shown to contribute significantly to activated
myofibroblasts in various types of hepatic
injury. The other potential cellular origins are
bone-marrow-derived mesenchymal cells
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Figure 2. Hepatic wound healing.Normal hepatic structure (1) is disrupted following injury to the liver (2) when
hepatocytes release factors that start an inflammatory process via recruitment of leukocytes to the site of injury.
Thisoccurs inparallel to localactivationofKupffercells,whichproducecytokinesandtoxic free radicals (Reactive
oxygen and nitrogen species, RNS andROS). (3) Profibrogenic cytokines and chemokines, and free radicals, as
well as apoptotic and necrotic bodies, together establish a paracrine signal leading to transdifferentiation of
quiescent hepatic stellate cells (q-HSCs) into activated myofibroblasts [activated hepatic stellate cells
(a-HSCs)]. This step in HSC activation is known as the initiation phase, which renders the cells susceptible
to cytokines, growth factors and other stimuli. Following this phase, perpetuation occurs – a phase in which
the differentiated phenotype of the cell is amplified by mediators via autocrine signals. (4) In addition to
a-HSCs, other cells, such as portal fibroblasts, bone-marrow-derived cells and epithelial compartments
within the liver, can contribute to the activated pools of myofibroblasts during liver injury. (5) After cessation
of injury, activated myofibroblasts undergo apoptosis, collagen fibres become more organised and scar
tissue is removed. (6) This occurs in parallel to hepatocyte regeneration and remodelling, which restores the
damaged tissue to the normal state. However, in the case of persistent injury, the normal healing process is
interrupted (7) and persistent inflammation and/or infection results in chronic myofibroblast activation and
proliferation, as well as excessive accumulation of extracellular matrix (ECM) components, which promotes
and establishes hepatic fibrosis.
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(Refs 20, 21), fibrocytes (Ref. 22) and portal
fibroblasts (Refs 23, 24). Recent evidence also
suggests that biliary epithelial cells and
hepatocytes may contribute to the hepatic
myofibroblast pool by undergoing epithelial–
mesenchymal transition (EMT) (Refs 25, 26, 27,
28). However, there is a need for further
lineage-specific studies to explore EMT
processes in liver fibrogenesis. The contribution
of each cellular source to activated hepatic
myofibroblasts varies according to the type of
liver injury. For instance, myofibroblasts
derived from portal fibroblasts – the fibroblasts
surrounding the biliary tree – are important
fibrogenic cells in the early stages of biliary
fibrosis (Refs 23, 29, 30). In cases of rapid biliary
injury, such as that seen in biliary atresia,
biliary epithelial cells play an important role in
biliary fibrosis via an EMT process (Ref. 26). It
is possible that the different potential sources of
fibrogenic cells in various liver diseases or
different lobular regions of the diseased liver
could lead to antifibrotic therapies that are
specifically targeted only to certain
subpopulations or diseases.
Hepatic stellate cell transdifferentiation
After hepatic injury of any aetiology, HSCs
undergo a highly regulated transdifferentiation
process from quiescent cells into proliferative
and fibrogenic myofibroblasts. This change in
the phenotype of HSCs is also known as ‘HSC
activation’ and has been divided into two
phases (Ref. 2). First, there is an initiation
phase, which renders the cells susceptible to
cytokines, growth factors and other stimuli, and
occurs in parallel with transcriptional
alterations in early response genes. Following
this, perpetuation occurs – a phase in which the
differentiated phenotype of the cell is amplified
by soluble and insoluble mediators (Ref. 2).
Initiation of HSC transdifferentiation is largely
due to paracrine stimulation, whereas the
perpetuation of the differentiated state involves
autocrine as well as paracrine loops (Fig. 2).
Ultimately HSC transdifferentiation is
characterised by the development of activated
hepatic myofibroblasts with proliferative,
contractile, migratory, fibrogenic and
inflammatory properties (Ref. 2).
Current knowledge suggests that the initial
signals driving HSC transdifferentiaion are
produced by injured cells, pathogens,
inflammatory mediators and alterations in the
local ECM. Injured hepatocytes, Kupffer cells
and other nonparenchymal cells produce
necrotic cell debris, apoptotic bodies (Refs 31,
32, 33), reactive oxygen and nitrogen species
(ROS and RNS) (Refs 34, 35), as well as other
active mediators, all of which signal through
specific activation pathways and can be sensed
by HSCs. In addition, early alterations in the
mechanical stiffness of the whole tissue precede
matrix deposition and can trigger
transdifferentiation of HSCs (Ref. 36).
Pattern-recognition receptors, which recognise
conserved pathogen or host-associatedmolecular
patterns, are expressed by different cells of the
immune system and act as a first line of defence
against injury or infection (Ref. 10). Recent
advances in the field have identified the
expression of pattern-recognition receptors such
The origins of liver myofibroblasts
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Figure 3. The origins of liver myofibroblasts.
During the development of hepatic fibrosis,
myofibroblasts are derived from a number of
different sources. Hepatic stellate cells are the
best characterised source. Other potential cellular
origins are bone-marrow-derived mesenchymal
cells, portal fibroblasts and epithelial
compartments in the liver, such as cholangiocytes
and hepatocytes. Biliary epithelium and
hepatocytes can contribute to the activated
myofibroblast pool by epithelial–mesenchymal
transition.
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as toll-like receptor (TLR) 4 and TLR9 in hepatic
myofibroblasts (Refs 33, 37). Subsequently, it has
been shown that DNA from apoptotic
hepatocytes, which are rich in cytosine-
phosphate-guanine (CpG), can activate TLR9 in
HSCs and contribute to the activated phenotype
in these cells (Ref. 33). This observation may
explain why apoptosis of hepatocytes results in
activation of HSCs and development of hepatic
fibrosis (Ref. 38, 39). In addition, a recent study
using TLR4 mutant mice has confirmed a role
for TLR4 in liver fibrogenesis (Ref. 40). It
therefore appears that activation of several
pattern-recognition receptors can act as a
primary signal for HSC transdifferentiation
(Ref. 10). In addition, HSCs have recently been
shown to act as professional antigen-presenting
cells (Ref. 41). The ability of these cells to
process and present antigens to immune cells
can itself help to activate immune-dependent
mechanisms, which subsequently influence the
transdifferentiation process in HSCs. However,
the impact of various immune cells on
transdifferentiation of HSCs warrants further
study. It is clear, therefore, that there is a
network of multiple signals, as well as different
cell types, that are influenced by liver injury
and drive transdifferentiation in quiescent HSCs.
Maintaining the activated phenotype
Transdifferentiation of quiescent HSCs to a
myofibroblast phenotype does not appear to be
a transient event. Instead, the activated
myofibroblasts state is maintained by paracrine
signalling (e.g. ROS and RNS) from other types
of liver cell, including hepatocytes,
cholangiocytes and Kupffer cells (Refs 2, 35, 42).
HSCs themselves develop new autocrine
pathways, including those involving
transforming growth factor b (TGF-b) (Refs 43,
44), angiotensin II (Refs 45, 46), platelet-derived
growth factor (PDGF) (Ref. 47), monocyte
chemoattractant protein 1 (MCP1) (Refs 48, 49)
and vascular endothelial growth factor (VEGF)
(Ref. 50), which maintain the activated state of
the myofibroblasts and drive fibrogenesis. One
of the critical events in this regard, is that HSCs
upregulate new membrane receptors and
signalling proteins that prime these cells to
respond to inflammatory mediators and growth
factors, such as interleukin 6 (Ref. 51), TGF-b
(Refs 43, 44) and PDGF (Ref. 47). The alteration
in ECM components during this phase actively
regulates HSC behaviour. Different matrix-
associated molecules, such as TIMP1, integrins
and other adhesion molecules, contribute to
HSC survival and perpetuation of the activated
myofibroblast phenotype (Ref. 52, 53). Constant
signals from a stable chronic infection and/or
injury through pattern-recognition receptors
may also directly regulate the survival and
function of HSC-derivedmyofibroblasts (Ref. 10).
MMP/TIMP production by HSCs
Activated hepatic myofibroblasts proliferate and
migrate at the sites of liver injury, secreting
large amounts of ECM and regulating ECM
degradation. They express a combination of
MMPs and their specific TIMPs. In the early
phases of liver injury, HSCs transiently express
MMP3 (stromelysin 1), MMP13 (collagenase 3)
and uroplasminogen activator, and exhibit a
matrix-degrading phenotype, all of which
enables them to migrate toward the site of
injury (Ref. 54). In the later stages of liver injury
and HSC activation, the expression pattern
changes, and the cells express a combination of
MMPs, which have the ability to degrade
normal liver matrix while inhibiting
degradation of the fibrillar collagens that
accumulate in liver fibrosis. This new
expression pattern is characterised by the
combination of pro-MMP2 and membrane type
1 (MT1) MMP expression, which drives
pericellular generation of active MMP2 and
local degradation of subendothelial matrix,
facilitating replacement with high-density
interstitial matrix (Ref. 54). In addition, there is
a marked increase in the expression of TIMP1,
leading to a more global inhibition of
degradation of fibrillar liver collagens by
interstitial collagenases (MMP1/MMP13). As a
consequence, normal matrix homeostasis is
severely disrupted in favour of the net
deposition of fibrillar collagen, non-collagen
ECM molecules and integrin ligands.
Neuroendocrine differentiation and
cancer: implications for wound healing
Neuroendocrine phenotype
Neuroendocrine cells are scattered in various
organs of the body and have endocrine
phenotypes that share some of the structural,
functional and metabolic properties of neurons.
Advances in molecular pathology have led to
the identification of several markers in these
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cells. Neuroendocrine cells typically contain
secretory granules, called large dense-core vesicles
because of their characteristic appearance upon
electron microscopy. In addition to peptides, these
granules also contain one or more chromogranin/
secretogranin proteins. They express markers such
as chromogranin A, glycolipid A2-B4, S-100
protein, neural cell adhesion molecule, neuron-
specific enolase and synaptophysin (Refs 55, 56,
57). These markers have different specificities and
sensitivities in identifying the neuroendocrine
phenotype of a cell; many participate in various
intracellular excretory activities of cells, such as
packaging of hormones and neuropeptides, or
modulation of exocytosis and neurotransmitter
release in synapses.
Parathyroid-hormone-related peptide was
previously identified as the factor responsible
for the syndrome of humoral hypercalcaemia of
malignancy and is also a classical
neuroendocrine peptide that is involved in
growth, differentiation and angiogenesis in
various tissues (Ref. 58). In addition, a wide
range of neuropeptides are produced by
neuroendocrine cells or tissues, including
serotonin, neurotrophins, endogenous opioid
peptides, somatostatin, cannabinoids and
calcitonin (Refs 55, 57, 59, 60, 61). These factors
commonly regulate growth and survival in
various cells or tissues.
Little is known of the functional role of
neuroendocrine cells in many organs. It has been
suggested that they probably serve a paracrine or
local regulatory role. Neuroendocrine
differentiation has been found in a subgroup of
various carcinomas, including prostate, breast,
stomach, colorectal and non-small-cell lung
cancer (Refs 62, 63, 64, 65, 66, 67, 68). In many of
these tumours, neuroendocrine differentiation
has adverse prognostic effects, suggesting an
integral role for neuroendocrine factors in the
regulation of the malignant phenotype (Refs 62,
63, 64). The detailed molecular mechanisms
underlying the observed behaviour are mainly
undefined but the neuroendocrine cells of the
tumour probably play a significant role during
tumour growth, angiogenesis and metastasis
(Refs 62, 64, 69, 70). The histogenesis and origins
of neuroendocrine cells in the tumour
environment are not clear. However, it may
involvea local transdifferentiationprocess (Ref. 62).
Cancers have beendescribed aswounds that do
not heal (Ref. 71), suggesting that both tumours
and wounds may be part of a continuum.
Indeed, there are similarities between tumour
stroma generation and wound healing. This
includes various features that can regulate
growth, differentiation or angiogenesis in both
the wound and tumour environment. In fact,
persistent injuring stimuli result in
inflammation and continuous wound healing –
two mechanisms that lead to accentuated scar
tissue formation or fibrosis and have frequently
been linked to cancer formation (Refs 71, 72).
We have recently coined the phrase ‘hepatic
inflammation–fibrosis–cancer axis’ to reflect
this phenomenon (Ref. 73).
During chronic hepatic injury, different types of
liver cells acquire a neuroendocrine phenotype.
Given the putative role of the neuroendocrine
system in the regulation of growth and survival
in various conditions, and the shared
similarities between tumours and wounds, the
neuroendocrine compartment of the inflamed
liver might be expected to regulate cell growth,
migration and angiogenesis during wound
healing. In fact, there is increasing evidence that
local neuroendocrine factors do indeed
influence wound healing and fibrogenesis in
many organs (Refs 5, 6, 74, 75, 76, 77).
Neuroendocrine compartments in the
chronic-injured liver
In the diseased liver, atypically proliferating
cholangiocytes acquire a neuroendocrine
phenotype (Ref. 55). These cells, also known as
reactive bile ductules, have been identified as
one of the major contributors to the production
of various neuroendocrine factors in diverse
liver pathologies, and appear at interface zones
where maximal cell death and inflammation
occurs (Ref. 55). Proliferation of cholangiocytes
precedes the development of cirrhosis in most
liver diseases, including chronic cholestasis and
biliary cirrhosis, alcoholic liver disease and
chronic toxic liver injuries. This cholangiocyte
component of the local neuroendocrine system
in the injured liver has been widely studied in
recent years (Refs 55, 57, 59, 61).
Hepatic progenitor cells, also known as liver
oval cells, lie within or immediately adjacent to
the canal of Herring (Ref. 78) and express
neuroendocrine proteins, such as chromogranin-
A, neural-cell-adhesion molecule, parathyroid-
hormone-related peptide, S-100 protein,
neurotrophins and neurotrophin receptors
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(Refs 56, 57, 79). These cells are activated to
proliferate upon chronic liver damage in
situations where the proliferation of hepatocytes
is inhibited, which includes non-alcoholic
steatohepatitis, chronic cholestatic liver disease,
chronic alcoholic hepatitis and viral hepatitis.
Progenitor cells differentiate into hepatocytes
and contribute to the pool of reactive bile
ductules during the course of liver disease. In
addition to progenitor cells and reactive bile
ductules, small hepatocytes in periportal regions
express chromogranin A (Ref. 79). These newly
formed intermediate hepatocytes are observed in
chronic conditions where there is activation of
progenitor components (Ref. 79).
HSCs,themainplayersintheliverwound-healing
process, share a number of different markers with
neuroendocrine cells and the cells of the nervous
system (Ref. 80). They express synaptophysin,
which is one of the factors primarily correlated
with neuroendocrine differentiation (Refs 56, 81,
82). HSCs also express neutrophins and neural
cell adhesion molecules (Ref. 83). Generation
of neuroendocrine factors by HSCs may help to
maintain the activated myofibroblast phenotype
through autocrine loops. However, what is
potentially more central to the process is that
upon transdifferentiation HSCs upregulate
many receptors of neuroendocrine factors, which
renders them susceptible to neuroendocrine
regulation in wound healing. This issue will be
discussed in more detail below.
Which factors trigger neuroendocrine
differentiation in the injured liver?
Neuroendocrine differentiation in the liver is often
associated with the presence of cellular stress
and inflammation (Refs 55, 84). For instance,
ductular reactions in cholangiocytes are usually
accompanied by periductal inflammation, which
is presumed to trigger the reaction (Refs 55, 85,
86). The possible role of hepatic inflammation in
the development of neuroendocrine differentiation
is also supported by studies of cancer (Refs 70, 84).
It has been shown that interleukin 6 (IL-6) and
tumour necrosis factor (TNF) a – two important
cytokines in the liver – regulate both growth and
neuroendocrine differentiation in different types of
experimental cells, as well as human cancer cells
(Refs 70, 84). Several recent in vitro studies with
cancer cells have demonstrated that IL-6 can
promote neuroendocrine differentiation through
different intracellular signal-transduction
pathways, including the phosphatidylinositol 3-
kinase, signal transducers and activators of
transcription 3 (STAT3), and mitogen-activated
protein kinase (MAPK) pathways (Refs 70, 87, 88).
However, there is clearly a need to study how
much of this data can be extrapolated to liver
inflammation and fibrosis.
In addition, signals derived from the ECM can
also influence neuroendocrine functions in bile
duct epithelial cells. It has been reported that
interaction of these cells with the surrounding
matrix – in particular collagen type IV and
matrix heparan sulfate proteoglycan perlecan –
induces neuroendocrine differentiation
(Ref. 56). This is consistent with the fact that
reactive bile ductules are always surrounded by
basement membrane containing these ECM
components. Therefore, the neuroendocrine
phenotype in cholangiocytes and other cellular
populations in the liver can be regulated by
signals from both the matrix and inflammatory
factors. However, the specific cellular and
molecular players that promote neuroendocrine
differentiation in the liver remain to be identified.
Neuroendocrine regulation of
myofibroblast differentiation and wound
healing
As discussed earlier, transdifferentiation of HSCs
into activated myofibroblasts is one of the pivotal
events during wound healing and fibrogenesis in
the injured liver, and can be subdivided into an
initiation phase and a perpetuation phase. After
liver injury, inflammatory cells may directly
contribute to this transdifferentiation; but they
are not likely to provide all the growth factors
necessary for maintaining or accentuating the
activated phenotype at later stages. However,
induction of neuroendocrine differentiation in
cholangiocytes and oval cells in response to
inflammation and/or other mechanisms can
contribute to maintenance of the activated state
of HSCs. This may occur in parallel to the
expression of various neuroendocrine receptors
during HSC differentiation, which renders these
cells responsive to regulation (Fig. 4). Many of
these factors can further affect hepatic wound
healing by influencing neoangiogenesis,
inflammation and hepatocyte regeneration. It
should also be considered that HSCs have their
own neuroendocrine features that may
contribute to their fibrogenic activities via
autocrine mechanisms. Here we discuss some
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of the recently identified neuroendocrine factors
that regulate the production and function of
HSC-derived myofibroblasts in the liver
(Table 1). It is interesting that many medications
that could potentially modulate the effect of
neuroendocrine factors and prevent fibrogenesis
are already in routine clinical practice in other
contexts and have established safety records,
making them very attractive candidates for
rapid translation into clinical trials. However, it
is important to stress that the regulation of HSC
biology by these factors has not yet been fully
defined and may be more complex than initially
anticipated. Furthermore, there is no evidence
that neuroendocrine factors regulate the
functions of HSC-derived myofibroblasts
exclusively. In fact, the role of these factors in
the differentiation of other cellular sources of
liver myofibroblasts is possible and warrants
further study.
Neutrophins and their receptors
Neutrophins were originally reported to regulate
growth and development in the nervous system.
A rapidly growing body of evidence now
suggests that neutrophins also play profound
Local neuroendocrine regulation of stellate cell transdifferentiation
Expert Reviews in Molecular Medicine © 2008 Cambridge University Press
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Figure 4. Local neuroendocrine regulation of stellate cell transdifferentiation. Normal hepatic structure is
disrupted following injury to the liver, subsequently, quiescent stellate cells (q-HSCs) transdifferentiate into
activated myofibroblasts (a-HSCs). At the same time, inflammation and altered matrix components induce
neuroendocrine differentiation in proliferating bile ducts, oval cells and even HSCs. These cells produce
various neuropeptides – endocannabinoids, serotonin, opioids, neutrophins – which contribute to
maintenance and amplification of the differentiated phenotype in activated myofibroblasts. Neuroendocrine
factors contribute to various aspects of profibrogenic activity in activated myofibroblasts, such as
contraction, migration, proliferation and extracellular matrix production.
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roles in various non-neuronal tissues. The
neurotrophin family consists of nerve growth
factor (NGF), brain-derived neurotrophin
(BDNF), neurotrophin 3 and neurotrophin 4/5.
The neutrophin receptors are high-affinity
neurotrophin tyrosine kinase receptors TrkA,
TrkB and TrkC, as well as the ‘low’-affinity pan-
neurotrophin receptor p75NTR, which belongs
to the TNF-receptor superfamily (Table 1).
Activated myofibroblasts, cholangiocytes and
hepatocytes secrete NGF and express the
receptors for different neutrophins (Refs 83, 89,
90). A recent study has shown that HSCs
derived from p75-knockout mice showed
significantly reduced differentiation into
activated myofibroblasts, as well as reductions
in the protein expression of smooth muscle
actin and collagen I (Ref. 91). This effect was
ameliorated by transfection with the
intracellular portion of p75, demonstrating a
critical role for this receptor in HSC activation.
Interestingly, an exon-3 knockout of p75, which
retains an intact intracellular domain but lacks
the structural requirements for interaction with
its ligand, supports the activation of HSCs and
the development of liver fibrosis in a
predictable manner after carbon tetrachloride
(CCl4) intoxication (Iredale, J.P. and Kendall,
T.J., University of Edinburgh, UK, pers.
commun.). It has been suggested that p75
Table 1. Local neuroendocrine regulation of hepatic fibrosis
Neuroendocrine
factor
Producer cell type Known
Receptors
Effect on HSCs and fibrosis
Nerve growth factor
and other
neurotrophins
Myofibroblasts
Cholangiocytes
Hepatocytes
Tyrosine kinase
receptors (TrkA,
TrkB, TrkC)
Pan-
neurotrophin
receptor p75NTR
p75NTR induces HSC
differentiation or apoptosis
during fibrogenesis;
NGF regulates migration and
differentiation of fibroblasts
by TrkA-dependent mechanisms
Serotonin Platelets
Myofibroblasts?
(Storage/release)
5HT1–5HT7 Expression of 5HT1B, 5HT2A
and 5HT2B is induced with HSC
activation. 5-HT synergises with
PDGF to stimulate increased
HSC proliferation. 5-HT
significantly increases TGF-b1
and Smad4 in HSCs
Opioids Cholangiocytes
Hepatocytes
d, m, k Activation of d opioid receptor
increases TIMP1 and
procollagen I. m-opioid receptor
activation inducesproliferation of
HSCs. In vivo inhibition of opioid
system reduces fibrosis in
cholestatic and
dimethylnitrosamine-induced
liver injury
Cannabinoids Probably at site of
injury (on demand) by
receptor-stimulated
cleavage of lipid
precursors (Specific
cells?)
CB1, CB2,
vanilloid
Genetic ablation or
pharmacological blockade of the
CB1 receptor attenuates hepatic
fibrosis in different models.
However, CB2 signalling is
antifibrogenic in vivo and in vitro
Abbreviations: 5-HT, 5-hydroxytryptamine; CB-1, cannabinoid receptor 1; CB-2, cannabinoid receptor 2; HSC,
hepatic stellate cell; NGF, nerve growth factor; PDGF, platelet-derived growth factor; RNS, Reactive nitrogen
species; ROS, reactive oxygen species; TIMP-1, Tissue inhibitor of metalloproteinase 1.
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signalling through Rho promotes HSC
differentiation into active myofibroblasts
(Ref. 91). However, the regulation of HSCs by
neutrophin receptors appears to be more
complicated and warrants additional research.
NGF induces apoptosis in activated HSCs via a
p75-dependent mechanism (Ref. 90). p75NTR
may therefore function not only as a regulator
of HSC transdifferentiation but may also limit
the fibrogenic response by exerting a negative
influence on the life span of the activated
myofibroblasts. A similar regulatory system has
been observed in fibroblast–myofibroblast
differentiation in other situations. Quiescent
fibroblasts express TrkA constitutively, whereas
myofibroblats express both TrkA and p75, and
all produce NGF (Refs 92, 93). NGF regulates
the migration and differentiation of fibroblasts
by a TrkA-dependent mechanism, and it also
induces apoptosis of activated myofibroblats
via the p75 receptor. Thus, it appears that
different temporal expression patterns of TrkA/
p75 might regulate the final pathological
process (Ref. 93). Together, these data suggest
an important role for neutrophins and their
receptors during liver wound healing.
The serotonin system
Serotonin or 5-hydroxytryptamine (5-HT) has
been recognised for more than 50 years as an
effector on various types of smooth muscle cell
and subsequently as an agent that enhances
platelet aggregation and as a neurotransmitter
in the nervous system. Despite the critical role
of serotonergic mechanisms in the central
nervous system, the brain actually contains very
little serotonin in relative terms. About 95% of
serotonin is produced in enterochromaffin cells
throughout the gut. Enterochromaffin cells
produce far more serotonin than is required by
the gut and it overflows into the blood, where it
is then taken up and concentrated in platelets,
the only source of blood serotonin. After its
release by platelets, serotonin is absorbed
rapidly by various cell types via the specific
membrane-bound serotonin transporter (Ref. 94).
Molecular cloning has revealed an unexpected
diversity of receptor subtypes in serotonin
signalling (5HT1–5HT7), which are coupled to
different, but overlapping, transmembrane-
signalling mechanisms (Table 1). The expression
of serotonin receptors has been reported in
hepatocytes, and the authors suggested a key
role for serotonin in liver regeneration (Ref. 95).
Although platelets are the main source of
serotonin in the injured liver, proliferating
cholangiocytes and HSCs can also secrete
serotonin (Ref. 59, 74). Rat and human HSCs
express the 5HT1B, 5HT1F 5HT2A 5HT2B and
5HT7 receptors, with expression of 5HT1B,
5HT2A and 5HT2B receptors induced upon
HSC activation (Ref. 74). Serotonin significantly
increases the expression of TGF-b1 and Smad4
in HSCs (Ref. 96) and synergises with PDGF to
stimulate increased HSC proliferation (Ref. 74).
In addition, HSCs express a functional
serotonin transporter (SERT) and can
potentially regulate the concentration of
serotonin in the vicinity of injured liver cells
(Ref. 74). Therefore, serotonin may actively
regulate hepatic fibrogenesis.
Endogenous opioid peptides
Opiates have been known for decades for their
role in pain management. They have been
shown to be produced endogenously in the
body and to regulate cell growth, differentiation
and survival in neuronal and non-neuronal
cells. Endogenous opioid peptides act by
interacting with three classical opioid receptors:
the m, d and k receptors (Table 1). Three
endogenous families of classical opioid
peptides have been identified in the body: the
enkephalins, endorphins and dynorphins. Each
family is derived from a distinct precursor
polypeptide and has a characteristic anatomical
distribution (Ref. 97).
Studies from the 1980s in patientswith primary
biliary cirrhosis represent the earliest evidence of
a correlation between endogenous opioids and
liver disease (Ref. 98). It has been demonstrated
that bile duct epithelium and hepatocytes
express preproenkephalin mRNA following
injury, which encodes Met- and Leu-enkephalin
peptides (Refs 99, 100). Recent studies on the
role of opioids in the pathophysiology of
chronic liver injury demonstrate potentially
novel targets for antifibrotic therapies (Refs 75,
97, 101). Recently, we identified d-opioid-
receptor expression following transdifferentiation
of HSCs. Activation of this receptor by different
d-opioid agonists increases expression of the
genes encoding TIMP1 and procollagen I and
inhibits apoptosis of activated myofibroblasts
(Ref. 75). Subsequent work has demonstrated that
stimulation of opioid receptors activates calcium-
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dependent protein kinase C, extracellular-signal-
regulated kinase, phosphatidylinositol 3-kinase
(PKC–ERK–PI3K) signalling, which then
mediates the effect of endogenous opioids on
HSC proliferation and collagen synthesis.
Furthermore, in vivo inhibition of the opioid
system in a model of chronic cholestatic liver
disease and in dimethylnitrosamine (DMN)-
induced liver injury significantly prevented the
development of hepatic fibrosis (Ref. 75, 102). It
has been suggested that during chronic liver
injury, HSC-derived myofibroblasts express
opioid receptors rendering them susceptible to
opioid peptides produced by epithelial
compartments in the liver, which can then
contribute to maintenance of the activated
phenotype in these cells.
Endocannabinoids
The role of the endogenous cannabinoid system in
the pathophysiology of liver disease has attracted
a great deal of recent attention. Endogenous
cannabinoids (endocannabinoids) are lipid
mediators that include amides and esters of
long-chain polyunsaturated fatty acids. Two
arachidonic acid derivatives,
arachidonoylethanolamide (anandamide) and 2-
arachidonoylglycerol (2-AG) are the most
biologically active endocannabinoids described
so far (Ref. 103). These molecules bind to two
G-protein-coupled receptors, CB1 and CB2,
although other targets, such as vanilloid
receptors have been identified (Table 1). Unlike
classical neurotransmitters and neuropeptides,
endocannabinoids are not stored in intracellular
compartments but are produced ‘on demand’
by receptor-stimulated cleavage of lipid
precursors (Ref. 104).
Following transdifferentiation, HSCs express
both CB1 and CB2 receptors (Ref. 105). It has
been reported that CB2 signalling in HSCs is
antifibrogenic (Ref. 106) and that stimulation of
activated HSCs by anandamide or 2-AG
provokes cell death by redox-sensitive
mechanisms, not via cannabinoid receptors
(Ref. 105, 107). However, epidemiological
studies have demonstrated that daily cannabis
smoking is an independent risk factor for rapid
progression of fibrosis in chronic hepatitis C
patients (Ref. 108). A further study, carried out
in three mouse models of hepatic fibrogenesis,
identified that genetic ablation or
pharmacological blockade of the CB1 receptor
significantly attenuated development of hepatic
fibrosis (Ref. 109). This inhibition of CB1
receptor signalling was accompanied by
decreased expression of TGF-b – an important
profibrogenic cytokine in the injured liver – and
occurred in parallel to the reduced proliferation
and increased apoptosis of activated
myofibroblasts in vivo and in vitro. Taken
together, these studies suggest that CB1
signalling is the dominant pathway in hepatic
fibrogenesis in response to factors that can
activate both cannabinoid receptors (Ref. 110)
and propose an intriguing role for this system in
the regulation of hepatic wound healing.
Antagonism of the CB1 receptor, along with
potentiation of the CB2 receptor, may prove to
be an effective antifibrotic therapy in the future.
This may be realised soon, with clinical trials of
the CB1 antagonist rimonabant already under
way in the study of obesity.
Future perspectives and therapeutic
potentials
The role of the neuroendocrine system in liver
disease is an important emerging theme that
has already shed new light on the molecular
mechanisms that regulate hepatic wound
healing and fibrogenesis. However, much
remains to be learned before this new
information can be exploited for therapies that
promote liver regeneration and limit fibrosis. In
particular, the presence of different receptors
with counteracting signalling events means that
fibrosis of the liver is a far from simple event.
For instance, serotonin induces profibrogenic
behaviour in HSCs, while at the same time
accelerating hepatocyte regeneration and
inhibiting cholangiocyte proliferation (Refs 74,
95). An ideal strategy to inhibit fibrogenesis
would be to inactivate the profibrogenic
serotonin receptors and simultaneously stimulate
those serotonin receptors that promote
hepatocyte regeneration. However, the identities
of the receptors responsible for mediating the
fibrogenic and regenerative properties of
serotonin are unknown. At different stages in
the time course of liver disease, the distribution
of neuroendocrine receptors can vary from one
cell type to another in a dynamic fashion. For
example, with bile duct ligation, d-opioid-
receptor expression gradually diminishes in
cholangiocytes (Ref. 111). By contrast, the same
receptor is not expressed in quiescent HSCs but
expert reviews
http://www.expertreviews.org/ in molecular medicine
12
Accession information: doi:10.1017/S146239940800063X; Vol. 10; e11; April 2008
&2008 Cambridge University Press
W
o
u
n
d
h
e
a
li
n
g
a
n
d
lo
c
a
l
n
e
u
ro
e
n
d
o
c
ri
n
e
re
g
u
la
ti
o
n
in
th
e
in
ju
re
d
li
v
e
r
is expressed following transdifferentiation in
response to cholestasis (Ref. 74). Such opposite
trends for expression of d-opioid receptor in
these two liver cell types may account for the
heterogenic effects of endogenous opioid
peptides on cholangiocytes and HSCs (Ref. 111).
Therefore, inhibition of the same signalling
event at different time points in liver disease
may result in distinct outcomes.
Infuture,weneedtofurtherdissect theexpression
and function of different neuroendocrine factors
and the related receptors in each cell population
of the liver with precise molecular biology
approaches. For example, the increasing
availability of cell-specific knockouts of different
serotonin receptors will enable a careful dissection
of the role of the various receptors in vivo.
Furthermore, there is an urgent need to confirm
the results in human cells and both normal and
diseased human tissues.
Serotonin antagonists and reuptake inhibitors
are used routinely for the management of
psychiatric disorders such as depression.
Naltrexone (a nonselective opioid-receptor
blocker) is clinically administered for the
treatment of cholestatic pruritis in primary
biliary cirrhosis and also in the management of
addiction and alcohol dependence (Refs 112,
113). CB1 antagonists are currently under trial
for the treatment of obesity (Ref. 114). The
antagonist used in a recent study on the role of
CB1 in liver fibrosis in mice is SR141716A
(rimonabant) (Ref. 108); this drug is currently
an available therapeutic option. Although there
have been no studies on the role of these drugs
in the progression of human liver disease, their
availability in clinical practice makes it likely
that clinical trials of these agents in chronic
fibrogenic hepatic disease will not be far off.
Portal hypertension, variceal bleeding and
systemic arterial vasodilatation are among the
main reasons for morbidity and mortality in
cirrhotic patients. It has been demonstrated that
some of the neuroendocrine factors, such as
endogenous cannabinoids and opioids,
contribute to the systemic vasodilatory state
seen in cirrhosis (Ref. 115). Therefore,
modulation of these systems can potentially
extend the life of cirrhotic individuals, not only
by slowing or reversing fibrogenesis, but also
by improving the associated hyperdynamic
circulatory state. CB1 receptor activation has
been linked to obesity and energy homeostasis,
and its inhibition can exert enhanced
antifibrotic effects by modulation of metabolic
risk factors (Ref. 116). An important study has
shown that serotonin plays a role in the
pathogenesis of steatohepatitis, and therefore
might represent a novel target for the
prevention and treatment of nonalcoholic
steatohepatitis (NASH) and its associated
fibrosis (Ref. 117). Opioid-receptor blockade by
naltrexone is an approved strategy for treatment
of alcohol dependence by reducing alcohol
craving and relapse in heavy drinkers, and it
may also prove to be a more effective
antifibrotic candidate in alcoholic patients.
Conclusion
It is clear that local neuroendocrine systems play a
critical role in the development of hepatic fibrosis.
Variousmodulatorsofdifferent componentsof this
system are available clinically and can be
potentially useful in patients with liver disease.
However, to achieve further successful
therapeutic goals through neuroendocrine
targeting in hepatic fibrosis, we need to consider
the timing of treatment in the course of disease
and the duration of the therapy, as well as cell-
and receptor-specific targeting. In addition,
appropriate pharmacokinetics and safety
margins of the drugs should be considered
when treating patients with liver disease.
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Further reading, resources and contacts
Publications
Iredale, J.P. (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid
organ. J Clin Invest 117, 539-548
An interesting review looking at progress in the field of liver fibrosis and specifically concentrating on the
different cell and animal models used to study the disease.
Friedman, S.L. and Bansal, M.B. (2006) Reversal of hepatic fibrosis – fact or fantasy? Hepatology 43, S82-S88
A provocative review that critically evaluates the increasingly accumulating evidence that liver fibrosis is a
reversible process in both animals and humans.
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Further reading, resources and contacts (continued)
Weiskirchen, R. and Gressner, A.M. (2005) Isolation and culture of hepatic stellate cells. Methods Mol Med 117,
99-113
A complete paper that explains methods for isolation of hepatic stellate cells from liver.
Mann, J. et al. (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2:
implications for wound healing and fibrogenesis. Cell Death Differ 14, 275-285
An excellent paper that presents the first evidence of epigenetic regulation that underlies myofibroblastic
differentiation of hepatic stellate cells.
Websites
The British Liver Trust website provides various resources for both patients and health professionals and
includes links to other websites of interest:
http://www.britishlivertrust.org.uk
The American Association for the Study of Liver Disease (AASLD) website provides guidelines on the
management of various liver diseases for professionals as well as numerous patient resources and links:
https://www.aasld.org
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Figure 1. The hepatic sinusoid and hepatocytes in the liver.
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Figure 3. The origins of liver myofibroblasts.
Figure 4. Local neuroendocrine regulation of stellate cell transdifferentiation.
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